Since the patent has lapsed, the CSP is no longer relevant. What Novo Nordisk stands to lose in Canada and beyond The expiry of Novo Nordisks semaglutide patent in Canada might look small on paper, but the consequences could be substantial
Secondary objectives were the demonstration of the superiority of tirzepatide for change in HbA1c, weight, and waist circumference
Physical activity plays a crucial role in both weight management and improving cholesterol levels
Retatrutide is compatible with a variety of biochemical and biophysical assay platforms , including receptor-binding assays, proteinprotein interaction studies, and reconstructed signaling pathway systems
With 101 million people living with diabetes and another 136 million in the prediabetic stage, India is fast emerging as a key market for GLP-1 agonist therapies